Zeynep Güneş Özünal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zeynep Güneş Özünal has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Akçahan Gepdi̇rEmen
Department of Pharmacology, Faculty of Medicine, Abant Izzet Baysal University, Bolu 14280, Turkey
1 shared publicationAli̇ Ucbek
Department of Pharmacology, Faculty of Medicine, Abant Izzet Baysal University, Bolu 14280, Turkey
1 shared publication- Metin Uysalol
Department of Pediatrics, İstanbul University İstanbul School of Medicine, İstanbul, Turkey
1 shared publication - Sinem Oral Cebeci
Department of Pediatric Emergency, Cerrahpaşa Medical Faculty, İstanbul University-Cerrahpaşa, Istanbul, Turkey
1 shared publication Özge Uzun
Department of Pharmacology, Faculty of Medicine, Abant Izzet Baysal University, Bolu 14280, Turkey
1 shared publication
Latest Publications
- 15 December 2016
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 79 (3) , 133
FARKLI İKİ HASTA AYNI GENETİK ÖZELLİKLER, MONOZİGOTİK İKİZLERDE RİSPERİDON İNTOKSİKASYONU: OLGU SUNUMU
Çocuk acil polikliniklere başvuru nedenleri arasında çocukluk yaş grubunda zehirlenmeler önemli yer tutmaktadır. Yaygın olarak kullanılan, istenmeyen etki olasılığı yüksek ilaçların uygunsuz kullanımı bu nedenler arasında dikkat çekecek sıklıktadır. Bu olgu sunumunda, aynı anda başlayan distonik kasılma şikayetiyle başvuran, öncesinde herhangi bir sağlık sorunu olmayan yedi yaşında monozigotik ikiz kardeşler sunulmuştur. Anahtar Kelimeler: Zehirlenme; risperidon; monozigot ikiz
- 15 December 2016
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 79 (3) , 133
FARKLI İKİ HASTA AYNI GENETİK ÖZELLİKLER, MONOZİGOTİK İKİZLERDE RİSPERİDON İNTOKSİKASYONU: OLGU SUNUMU
Çocuk acil polikliniklere başvuru nedenleri arasında çocukluk yaş grubunda zehirlenmeler önemli yer tutmaktadır. Yaygın olarak kullanılan, istenmeyen etki olasılığı yüksek ilaçların uygunsuz kullanımı bu nedenler arasında dikkat çekecek sıklıktadır. Bu olgu sunumunda, aynı anda başlayan distonik kasılma şikayetiyle başvuran, öncesinde herhangi bir sağlık sorunu olmayan yedi yaşında monozigotik ikiz kardeşler sunulmuştur. Anahtar Kelimeler: Zehirlenme; risperidon; monozigot ikiz
- Open Access
- 4 March 2014
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 7 (5) , 1285-1290
Effect of metformin on the human T98G glioblastoma multiforme cell line
Metformin is a guanidine derivative found in Galega officinalis that is commonly used to treat diabetes mellitus. The mechanism of action of metformin involves regulation of the adenosine monophosphate‑activated protein kinase/mammalian target of rapamycin signaling pathway, which is implicated in the control of protein synthesis and cell proliferation. This led to the hypothesis that metformin reduces the risk of cancer and slows tumor growth. Thus, in the present study, the effectiveness of metformin as an antiglioma agent was evaluated using the human T98G glioblastoma multiforme cell line. The viability of the T98G cells was assessed using a 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay. Apoptosis was monitored by measuring caspase‑3 levels, as well as by terminal deoxynucleotidyl transferase dUTP nick end labeling and staining with acridine orange and ethidium bromide. The results demonstrate that metformin reduced cell viability and caused apoptotic morphological changes in the T98G cells. Furthermore, the caspase‑3 levels in the metformin‑treated T98G cells were higher than those in the control cells. Metformin induced apoptosis in the T98G cell line in a concentration‑dependent manner. Metformin may provide an important contribution to the treatment of glioblastoma multiforme.
- 4 March 2014
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 7 (5) , 1285-1290
Open AccessEffect of metformin on the human T98G glioblastoma multiforme cell line
Metformin is a guanidine derivative found in Galega officinalis that is commonly used to treat diabetes mellitus. The mechanism of action of metformin involves regulation of the adenosine monophosphate‑activated protein kinase/mammalian target of rapamycin signaling pathway, which is implicated in the control of protein synthesis and cell proliferation. This led to the hypothesis that metformin reduces the risk of cancer and slows tumor growth. Thus, in the present study, the effectiveness of metformin as an antiglioma agent was evaluated using the human T98G glioblastoma multiforme cell line. The viability of the T98G cells was assessed using a 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay. Apoptosis was monitored by measuring caspase‑3 levels, as well as by terminal deoxynucleotidyl transferase dUTP nick end labeling and staining with acridine orange and ethidium bromide. The results demonstrate that metformin reduced cell viability and caused apoptotic morphological changes in the T98G cells. Furthermore, the caspase‑3 levels in the metformin‑treated T98G cells were higher than those in the control cells. Metformin induced apoptosis in the T98G cell line in a concentration‑dependent manner. Metformin may provide an important contribution to the treatment of glioblastoma multiforme.